NASDAQ: RDGTRidgetech Inc Stock
$1.36-0.13 (-8.72%)
Updated Jun 17, 2026
RDGT Price
$1.36
Fair Value Price
N/A
Market Cap
$7.96M
52 Week Low
$1.21
52 Week High
$760.50
P/E
0.6x
P/B
0.27x
P/S
0.07x
PEG
N/A
Dividend Yield
N/A
Revenue
$111.62M
Earnings
$12.41M
Gross Margin
-7.4%
Operating Margin
11.56%
Profit Margin
11.1%
Debt to Equity
1.06
Operating Cash Flow
$17M
Beta
1.05
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
RDGT Overview
Ridgetech Inc. operates as a holding company that oversees multiple subsidiary businesses. These subsidiaries are responsible for the wholesale, distribution, and retail sales of various pharmaceutical and other health-related products.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RDGT's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical Retailer
Industry Rating
D
RDGT
Ranked#1 of 4
Ranked#1 of 4
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.37 | C | |
| $1.80 | C | |
| $3.70 | F |
Be the first to know about important RDGT news, forecast changes, insider trades & much more!
RDGT News
Overview
Due Diligence Score
–
Industry Average (19)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RDGT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RDGT is good value based on its earnings relative to its share price (0.6x), compared to the US market average (12.4x)
P/E vs Market Valuation
RDGT is good value based on its earnings relative to its share price (0.6x), compared to the US Pharmaceutical Retailers industry average (-4.03x)
P/E vs Industry Valuation
RDGT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more RDGT due diligence checks available for Premium users.
Valuation
RDGT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0.6x
Industry
-4.03x
Market
12.4x
RDGT is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
RDGT is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
RDGT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.27x
Industry
44.95x
RDGT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RDGT's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
RDGT's Earnings (EBIT) of $12.91M... subscribe to Premium to read more.
Interest Coverage Financials
RDGT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$61.4M
Liabilities
$31.6M
Debt to equity
1.06
RDGT's short-term assets ($56.74M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RDGT's short-term assets ($56.74M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RDGT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RDGT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
RDGT's operating cash flow ($16.55M)... subscribe to Premium to read more.
Debt Coverage Financials
RDGT vs Pharmaceutical Retailer Stocks
Ridgetech Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.